NYSE:CO (Hong Kong) Also trade in: Germany

Global Cord Blood Corp

$ 6.47 0 (0%)
Volume: 19,187 Avg Vol (1m): 39,676
Market Cap $: 786.44 Mil Enterprise Value $: 92.95 Mil
P/E (TTM): 22.30 P/B: 1.62
Earnings Power Value 0
Net Current Asset Value 2.34
Tangible Book 3.91
Projected FCF 3.22
Median P/S Value 4.73
Graham Number 5.01
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
89.89% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CO: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.86, Med: 7.53, Max: 10000
Current: 10000
1.86
10000
Equity-to-Asset 0.53
Equity-to-Asset ranked lower than
68.81% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CO: 0.53
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.35, Med: 0.5, Max: 0.78
Current: 0.53
0.35
0.78
Interest Coverage No Debt
Interest Coverage ranked lower than
85.80% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
CO: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 1.77, Med: 21.65, Max: 10000
Current: 10000
1.77
10000
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.54
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 3.55%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 34.36
Operating Margin ranked higher than
92.68% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CO: 34.36
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 28.86, Med: 36.47, Max: 40.49
Current: 34.36
28.86
40.49
Net Margin % 23.71
Net Margin ranked higher than
92.05% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CO: 23.71
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 13.72, Med: 21.37, Max: 34.69
Current: 23.71
13.72
34.69
ROE % 7.20
ROE ranked higher than
85.64% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CO: 7.2
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -4.86, Med: 8.78, Max: 11.82
Current: 7.2
-4.86
11.82
ROA % 3.81
ROA ranked higher than
84.87% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CO: 3.81
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -3.67, Med: 4.24, Max: 7.93
Current: 3.81
-3.67
7.93
ROC (Joel Greenblatt) % 53.61
ROC (Joel Greenblatt) ranked higher than
93.73% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CO: 53.61
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -10.49, Med: 51.63, Max: 63.52
Current: 53.61
-10.49
63.52
3-Year Total Revenue Growth Rate 13.40
3-Year Revenue Growth Rate ranked lower than
55.30% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
CO: -3.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 5.7, Max: 34.4
Current: -3.8
0
34.4
3-Year Total EBITDA Growth Rate 4.80
3-Year EBITDA Growth Rate ranked lower than
66.21% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
CO: -11.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate 13.10
3-Year EPS w/o NRI Growth Rate ranked higher than
59.90% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
CO: 13.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 9.1, Max: 327.8
Current: 13.1
0
327.8

» CO's 30-Y Financials

Financials (Next Earnings Date: 2019-06-27)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:CO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 621991    SIC : 0
Compare TSE:4593 NAS:BCRX NAS:FIXX NAS:CERS XPAR:STAGR SHSE:603896 XPAR:ALCLS NAS:MGNX TSX:ADVZ NAS:ANIP SHSE:603590 SZSE:002022 NAS:VYGR NAS:KNSA NAS:YMAB NAS:NITE NAS:VCEL NAS:CCXI ASX:CUV NAS:CARA
Traded in other countries 6CB.Germany
Address 1 Garden Road, 48th Floor, Bank of China Tower, Central, Hong Kong, HKG, 100020
Global Cord Blood Corp, formerly China Cord Blood Corp, provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments & technologies such as cord blood transplants.

Ratios

Current vs industry vs history
PE Ratio (TTM) 22.30
PE Ratio ranked higher than
54.84% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
CO: 22.3
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 8.33, Med: 22.8, Max: 1150.52
Current: 22.3
8.33
1150.52
PE Ratio without NRI 22.30
PE without NRI ranked higher than
54.73% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
CO: 22.3
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 8.33, Med: 22.8, Max: 1150.52
Current: 22.3
8.33
1150.52
PB Ratio 1.62
PB Ratio ranked higher than
79.21% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CO: 1.62
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.93, Med: 1.62, Max: 5.18
Current: 1.62
0.93
5.18
PS Ratio 5.52
PS Ratio ranked higher than
65.84% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CO: 5.52
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.29, Med: 4.05, Max: 49.65
Current: 5.52
2.29
49.65
EV-to-EBIT 2.10
EV-to-EBIT ranked higher than
81.99% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CO: 2.1
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -315.1, Med: 4.1, Max: 162.9
Current: 2.1
-315.1
162.9
EV-to-EBITDA 2.10
EV-to-EBITDA ranked higher than
82.21% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CO: 2.1
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -315.1, Med: 4.1, Max: 162.9
Current: 2.1
-315.1
162.9
EV-to-Revenue 0.63
EV-to-Revenue ranked higher than
92.35% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CO: 0.63
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -0.2, Med: 1.7, Max: 49.7
Current: 0.63
-0.2
49.7
Shiller PE Ratio 27.50
Shiller PE Ratio ranked higher than
55.81% of 86 companies
in the Biotechnology industry.
Industry Max: 11472.38, Med: 42.91, Min: 0.02
CO: 27.5
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 24.08, Med: 48.48, Max: 86.29
Current: 27.5
24.08
86.29
Current Ratio 9.65
Current Ratio ranked higher than
74.58% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CO: 9.65
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.45, Med: 6.07, Max: 73.11
Current: 9.65
2.45
73.11
Quick Ratio 9.61
Quick Ratio ranked higher than
75.42% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CO: 9.61
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 2.43, Med: 6.01, Max: 73.11
Current: 9.61
2.43
73.11
Days Inventory 62.55
Days Inventory ranked higher than
70.27% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
CO: 62.55
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 14.08, Med: 56.43, Max: 78.07
Current: 62.55
14.08
78.07
Days Sales Outstanding 35.17
Days Sales Outstanding ranked higher than
68.86% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
CO: 35.17
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 35.17, Med: 68.62, Max: 85.62
Current: 35.17
35.17
85.62
Days Payable 25.72
Days Payable ranked lower than
77.24% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
CO: 25.72
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 22.87, Med: 30.04, Max: 35.81
Current: 25.72
22.87
35.81

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 1.23
Trailing Dividend Yield ranked higher than
50.00% of 226 companies
in the Biotechnology industry.
Industry Max: 44.35, Med: 1.08, Min: 0.03
CO: 1.23
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 1.05, Med: 1.2, Max: 1.38
Current: 1.23
1.05
1.38
Dividend Payout Ratio 0.30
Dividend Payout Ratio ranked lower than
100.00% of 131 companies
in the Biotechnology industry.
Industry Max: 2.63, Med: 0.28, Min: 0.01
CO: 0.3
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0, Med: 0, Max: 0.3
Current: 0.3
0
0.3
Forward Dividend Yield % 1.22
Forward Dividend Yield ranked lower than
51.13% of 221 companies
in the Biotechnology industry.
Industry Max: 44.35, Med: 0.95, Min: 0.08
CO: 1.22
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 1.23
Yield-on-Cost (5y) ranked lower than
63.01% of 219 companies
in the Biotechnology industry.
Industry Max: 65.06, Med: 1.56, Min: 0.03
CO: 1.23
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 1.05, Med: 1.2, Max: 1.38
Current: 1.23
1.05
1.38
3-Year Share Buyback Rate -14.70
3-Year Share Buyback Rate ranked lower than
53.56% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CO: -14.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -120.9, Med: -3.1, Max: 1.1
Current: -14.7
-120.9
1.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.65
Price-to-Tangible-Book ranked higher than
83.45% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CO: 1.65
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.07, Med: 1.71, Max: 5.41
Current: 1.65
1.07
5.41
Price-to-Projected-FCF 2.01
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
57.51% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
CO: 2.01
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.06, Med: 1.94, Max: 3.59
Current: 2.01
1.06
3.59
Price-to-Median-PS-Value 1.37
Price-to-Median-PS-Value ranked lower than
73.45% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CO: 1.37
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.57, Med: 1, Max: 10.33
Current: 1.37
0.57
10.33
Price-to-Graham-Number 1.29
Price-to-Graham-Number ranked higher than
74.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
CO: 1.29
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.7, Med: 1.4, Max: 14.13
Current: 1.29
0.7
14.13
Earnings Yield (Joel Greenblatt) % 47.86
Earnings Yield (Greenblatt) ranked higher than
95.65% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CO: 47.86
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -3389.4, Med: 23.15, Max: 2312.9
Current: 47.86
-3389.4
2312.9
Forward Rate of Return (Yacktman) % -8.56
Forward Rate of Return ranked lower than
74.07% of 135 companies
in the Biotechnology industry.
Industry Max: 107.61, Med: 11.41, Min: -475.79
CO: -8.56
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -8.6, Med: 2.1, Max: 21.1
Current: -8.56
-8.6
21.1

More Statistics

Revenue (TTM) (Mil) $ 146.02
EPS (TTM) $ 0.29
Beta 0.24
Volatility % 35.54
52-Week Range $ 5.67 - 10.12
Shares Outstanding (Mil) 121.55

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N